- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
5 Pharma Companies Cited by Industry Group For Practice Code Violations
Recently, the Prescription Medicines Code of Practice Authority announced in a press release that 5 pharmaceutical companies have breached the Association of the British Pharmaceutical Industry’s Code of Practice.
Recently, the Prescription Medicines Code of Practice Authority (PMCPA) announced in a press release that 5 pharmaceutical companies have breached the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice. The code reflects and extends beyond UK law, and is administered by the PMCPA as part of a self-regulatory system that covers prescription medicines.
PMCPA publicly reprimanded Sunovion Pharmaceuticals Europe LTD for allowing 1 of its managers to encourage staff to suggest to customers that they could face legal action if they did not consider lurasidone (Latuda) as part of a patient review. It was ruled that Sunovion was in breach for failing to maintain a high standard of ethical conduct in the field, and for providing verbal direction that advocated a course of action that would lead to a breach of the Code. The public reprimand appears on the front cover of the PMCPA November 2017 Code of Practice Review. Subsequently, the Code of Practice Appeal Board also required Sunovion to be audited.
Additionally, all of the following companies were cited for, among other issues, bringing discredit to and reducing confidence in the pharmaceutical industry:
- Bayer PLC. Bayer was cited for breaching 3 of the code's clauses by producing training and briefing material that suggested an unlicensed use for rivaroxaban (Xarelto).
- Astellas UK Limited. Astellas UK voluntarily admitted that, over a long period of time, a large number of its promotional materials, which referred to both solifenacin (Vesicare) and tacrolimus (Pograf), failed to include prescribing information for the 2 drugs. Astellas also admitted that it did not immediately act once the problem was discovered.
- Astellas Pharma Europe Limited. Astellas Pharma Europe voluntarily admitted that it had put out an electronic advertisement for Enzalutamide (Xtandi) that incorrectly referred to an indication and a publication as new. Additionally, the company had not followed its withdrawal process for the advertisement.
- A Menarini Pharma UK SRL. Menarini was cited for failing to certify and subsequently recertify its website, which provided information to the public and to patients, and for failing to act quickly when a link to an adverse event reporting site was missing.
The full case reports are published in the PMCPA November 2017 Code of Practice Review, and are also available at www.pmcpa.org.uk.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
